Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance
Hanna Helena Schalkwijk, Graciela Andrei, Robert Snoeck · 2024
Read Combined use of pritelivir with acyclovir or foscarnet suppresses evolution of HSV-1 drug resistance by Hanna Helena Schalkwijk, Graciela Andrei, Robert Snoeck (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11665824.txt.
Description
Hanna Helena Schalkwijk, Graciela Andrei, and Robert Snoeck test if a mix of herpes drugs holds back the growth of drug resistance. Their 2024 study passes herpes simplex virus through rounds in the lab. In each round, the dose of drug is raised.
Drugs in use now aim at the viral DNA polymerase. That leads to patterns of cross-resistance in patients whose immune system is weak. The team joined a helicase-primase inhibitor with one of two polymerase drugs. Mutations for resistance showed up fast when one drug was used on its own. With the drugs used as a pair, mutations were not there, or were held to the polymerase drugs. Resistance to the newer drug did not show up at all in one pair, in spite of many rounds. Strains that resisted both drugs came up in time, in one pair with a low dose only.
Catalog record
| CREATOR | Hanna Helena Schalkwijk, Graciela Andrei, Robert Snoeck |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |